Dr. Peter Ang, National Cancer Centre, SingaporeDr. Ang is the Director of Cancer Education at the National Cancer Centre, Singapore, involved in public and patient education programs.Dr. Ang is a practicing oncologist with a special interest in breast cancer and cancer genetics.He has been published in both international and local medical journals and has been a guest speaker within the community on cancer awareness.Dr. Ang received his medical training at the national University of Singapore and is a member of the Royal college of Physicians.
Ocular Oncology : Health Professionals - Specialists, Surgeons, Doctors, Dentists, Physician | PERSIFY â‰¡ Your Personal Assistant for Health Matters
Dr Peter Ang graduated from the National University of Singapore in 1991.
He obtained his Master of Medicine (Internal Medicine) and Membership of the Royal College of Physician (United Kingdom) in 1997.
In 2000, he was awarded the Ministry of Health Manpower Development Programme (HMDP) Scholarship to train at Dana Farber Cancer Institute, (Teaching Affiliates of Harvard Medical School), Boston USA.
His training was in general oncology with a particular focus on breast cancer and cancer genetics.
He had also qualified with the European Society of Medical Oncology (ESMO) certifying exam for medical oncologists topping the examination by being second in score for year 2000.
In 2001, he was one of the first to qualify with the Familial Cancer Risk Assessment and Management Exam certification by Institute of Clinical Evaluation for the practice of cancer genetics.
Prior to entering private practice, he was Senior Consultant Medical Oncologist and Director of the Cancer Education Service (2004) at the National Cancer Centre, Singapore.He was also a visiting consultant to KK Hospital to support the setup of the cancer genetics service which sees breast, ovarian and other gynaecological cancer patients.Recognised for his leadership and expertise as a breast cancer doctor, he was the leading cancer specialist of the Breast Cancer Workgroup (2002) for National Cancer Centre, Singapore and Singhealth cluster.He was involved in implementing the cluster Breast Cancer Health Management Plan (2003) incorporating the best breast cancer information with his team of doctors.
Dr Peter Ang was program leader for the Public Cancer Education with Singhealth Cancer Service Development Line (2004).
In clinical work, he was awarded the National Excellent Service Award (EXSA) in 2005.
He is involved in providing comprehensive oncology information and excellent care for patients with a wide range of cancers including lung cancer, stomach cancer, colorectal cancer, lymphoma, kidney cancer, breast cancer, ovary cancer, uterus cancer, and cervix cancer.
He has been actively involved in clinical and translational cancer research for many years, in breast, colon, lung and other cancers.
These have involved international trials of chemotherapy drugs currently in active use and newer targeted therapy drugs such as herceptin, lapatinib and sunitinib.
He was principal investigator for more than 10 clinical trials.Research work by Dr Ang has been published in both local and international journals including Journal of Clinical Oncology, Chest, Lancet Oncology, Seminars in Oncology, Cancer Epidemiology Biomarker & Prevention, Clinical Cancer Research, Clinical Genetics, Pharmacogenomics and Respiratory Medicine.His work on "Breast-cancer risk in families with mutations in PALB2" was published in the New England Journal of Medicine. (N Engl J Med.
2014 Oct 23371(17):1650-1)
He was the editor and main author of a book on breast cancer, "Illustrative Cases in Breast Cancer" (2006).
As an active researcher and cancer specialist, Dr Ang has also been a reviewer for several reputable medical journals, including American Journal of Clinical Oncology, World Journal of Surgical Oncology, Annals of Academy of Medicine Singapore and Oncology journal.He had investigated with collaborators on breast cancer in young women less than 35 years, non-small cell lung cancer using chemoradiotherapy, irinotecan (CPT-11 or Camptosar) in colorectal cancer patients, gemcitabine with pegylated liposomal doxorubicin (Caelyx, Doxil) as first-line chemotherapy in Asian women with metastatic breast cancer, lapatinib for Her2 positive locally advanced or metastatic breast cancer, and pharmacogenomic and pharmacogenetic studies in Asian breast cancer patients for drugs like doxorubicin, vorinostat and others.
Dr Ang is currently a Visiting Consultant to National Cancer Centre and is actively involved in research and teaching.He had been an active clinical teacher with the National University of Singapore and had been a speaker for Breast Cancer Foundation, Association of Women Doctors of Singapore and Singapore Cancer Society.
Being recognised as an authority in breast cancer, he had been one of the speakers for the first Singapore Medical Oncology Review Course (2007) and the first regional Asian Oncology Summit, 2009.
He had also been one of the regional keynote speakers for the Asia Breast Cancer Collaborative Group Meeting in 2010 & Guangzhou International Breast Cancer Symposium.
Dr Ang is fluent in English, Mandarin, and Hokkien, Teochew dialects.
He speaks some Malay and Bahasa and has looked after many Indonesian and Malay patients.
He has looked after Vietnamese, Russian, Myanmar, and Cambodian patients as well with the help of interpreters.
Breast cancer cases will rise in Singapore - AUG 25, 2004
Dr Peter Ang, a consultant with the National Cancer Centre, said that only those whose family history shows they are likely to have a mutation in a known cancer gene should do so, a relatively rare occurrence.
Thank You for Downloading!
1. Download ZoomInfo Grow
2. Run Installation Wizard
3. Check your inbox to Sign in to ZoomInfo Grow